Takeda Pharmaceutical Company Limited

Thank you for taking time out of your very busy schedule to join the FY24 Q2 earnings announcement by Takeda. I'm the master of ceremony, a head of IR. My name is O'Reilly. Thank you for this opportunity. Allow me to explain the language setting first. Please find the language selection button at the bottom of the Zoom screen. And if you wish to listen in Japanese, please choose Japanese. If English, English, and if you want to listen to the original voice, please keep it off.

In the Zoom language select button.

Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20F and our other SEC filings. But it is also referred to the important notice on page 2 of the presentation regarding forward-looking statements over non-IFRS financial measures, which will also be discussed during this call. Definitions of non-IFRS measures and reconciliations with comparable IFRS financial measures are included in the appendix to the presentation. Now we would like to start the presentation. Today we have President-CEO Christophe Weber, Chief Financial Officer Milano Furuta, R&D President Andy Plump presenting to you. And the presentation will be followed by Q&A. Let's get us started.